Across TCGA pan-cancer cohorts, E2F6P3 RNA is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated E2F6P3 data layer.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher E2F6P3 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated E2F6P3 expression acts as an unfavorable survival marker, although some lineages such as UCS and LUAD show a favorable association.
BLCA, KIRC, and UCEC are the cancer types where E2F6P3 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.